Questions include:
What is the potential magnitude of concern regarding antibiotic resistance? Is it clinically relevant to dermatologists in their day-to-day practice?
What can dermatologists do to slow the development of antibiotic resistance?
What is the mutant selection window?
How does the mutant selection window apply to topical antibiotics?